Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

ValiRx (VAL)

Price 0.725p on 26-12-2024 at 05:12:31
Change 0.00p 0%
Buy 0.75p
Sell 0.70p
Buy / Sell VAL Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: -
Day's Volume: 0
Last Close: 0.725p
Open: 0.00p
ISIN: GB00BLH13C52
Day's Range 0.00p - 0.00p
52wk Range: 0.715p - 6.05p
Market Capitalisation: £960k
VWAP: 0.00p
Shares in Issue: 132m

Sector: Medicine and Biotech

Listed In: FTSE AIM All-Share,

Recent Trades History ValiRx (VAL)
Buy/Sell Volume Trade Prc Trade Type Trade Time

Share Price History for ValiRx
Time period:
to
Date Open High Low Close Volume

Share News for ValiRx

IN BRIEF: ValiRx extends Ambrose Healthcare exclusivity agreement

20th Nov 2024 18:09

ValiRx PLC - Essex, England-based life sciences company - Says subsidiary ValiSeek Ltd has granted a six-month extension to Ambrose Healthcare Ltd offered under the exclusive option agreement inked in December 2023 to execute an exclusive sub-license of ValiSeek's VAL401 asset. Ambrose Healthcare now has a further six-month period during which it can choose to exercise the option. VAL401 is in development for the treatment of pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Read More

ValiRX adds to streak of deals with cancer cell test materials win

19th Nov 2024 11:39

(Alliance News) - ValiRX PLC announced on Tuesday it will provide more cancer cell detection materials to UK biotech firm Amply Discovery Ltd. Read More

AIM WINNERS & LOSERS: Woodbois subscription raises over GBP1 million

19th Nov 2024 10:39

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

IN BRIEF: ValiRx notes subsidiary's shipment of patient derived cells

18th Nov 2024 12:21

ValiRx PLC - Hatfield Heath, England-based life sciences company focused on early-stage cancer therapeutics and women's health - Says subsidiary Inaphaea BioLabs Ltd has made the first customer shipment of its first batch of patient derived cells, which are provided as part of its new range of assay ready reagents. ValiRX says, though the order value is immaterial, it endorses the group's product offering and potential revenue source. Chief Executive Officer Mark Eccleston says: "This first sale of our new product range is a major milestone for our commercialisation efforts." Read More

EARNINGS: Kendrick Resources loss narrows; Emmerson CFO to depart

27th Sep 2024 13:56

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

FTSE 100 Latest
Value8,136.99
Change0.00

Login to your account

Forgot Password?

Not Registered